{"id":"jnt-517-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"5-HT2C receptors are located in the hypothalamus and play a key role in appetite regulation. By selectively activating these receptors, JNT-517 enhances pro-opiomelanocortin (POMC) neuron signaling, which suppresses hunger signals and increases energy expenditure. This mechanism leads to reduced caloric intake and body weight reduction.","oneSentence":"JNT-517 is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:41.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Obesity or overweight with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT06971731","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-20","conditions":"Phenylketonuria","enrollment":120},{"nctId":"NCT07446400","phase":"PHASE1","title":"A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-03-20","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT06637514","phase":"PHASE2","title":"A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-07-16","conditions":"Phenylketonuria (PKU)","enrollment":10},{"nctId":"NCT05781399","phase":"PHASE1, PHASE2","title":"First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-10-31","conditions":"Phenylketonuria","enrollment":135},{"nctId":"NCT06628128","phase":"PHASE3","title":"A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With Phenylketonuria","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-06","conditions":"Phenylketonuria (PKU)","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JNT-517 Tablet","genericName":"JNT-517 Tablet","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JNT-517 is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite. Used for Obesity or overweight with weight-related comorbidities.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}